From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics
Vera S. Egorova , Ekaterina P. Kolesova , Maya V. Voronina , Evgenya R. Denisova , Anastasiia O. Syrocheva , Tatiana Pallaeva , Mazdak G. Hakemi , Andrey A. Zamyatnin Jr. , Konstantin I. Ivanov , Dmitry Kostyushev , Sergey Brezgin , Anastasiia Kostyusheva , Alessandro Parodi
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101116
Despite the growing body of literature on nanovaccines, focused analyses of platforms tested in and undergoing clinical investigation remain limited. This review addresses this gap by critically examining recent advancements and highlighting nanovaccine technologies that have undergone human clinical trials. Using an extensive search on clinicaltrials.org, we explored the diverse applications of nanovaccines, including leading SARS-CoV-2 candidates and platforms targeting other infectious diseases and cancers. We also highlighted foundational research that has enabled clinical investigation of nanovaccines over the past decade, highlighting their potential to address a range of medical conditions. While many technologies have been developed to combat SARS-CoV-2, several key innovations targeted a broader spectrum of diseases. This review details these technologies, focusing on their materials and mechanisms of action in inducing immune protection, while also exploring how nanomedicine facilitates nanovaccine development and introduces novel adjuvant concepts. Finally, we provided a retrospective analysis of the development journey of these platforms, offering insights into the intellectual and technological efforts behind their clinical translation. By bridging the gap between research and application, this review aims to give readers a comprehensive understanding of how nanovaccines progress from the laboratory to clinical practice.
Nanovaccine / Lipid nanoparticle / Virus-like nanoparticles / Outer membrane vesicles / Ferritin nanovaccines
| [1] |
Parodi A, |
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
Liu H, Chen H, Yang Z, Wen Z, Gao Z, Liu Z, |
| [9] |
|
| [10] |
|
| [11] |
Ahmad MZ, |
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
Statista. Number of coronavirus (COVID-19) cases, recoveries, and deaths worldwide as of May 2, 2023. Available at: https://www.statista.com/statistics/1087466/covid19-cases-recoveries-deaths-worldwide/. (Accessed January 30, 2026) |
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
Clinic M. Dengue fever. Available at: https://www.mayoclinic.org/diseases-conditions/dengue-fever/symptoms-causes/syc-20353078#:~:text=Dengue%20fever%20is%20most%20common,working%20on%20dengue%20fever%20vaccines. (Accessed January 30, 2026) |
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000; 19(1-2): 1-5. |
| [30] |
|
| [31] |
Institute NC. HPV and cancer. Available at: https://visualsonline.cancer.gov/details.cfm?imageid=11921. (Accessed January 30, 2026) |
| [32] |
|
| [33] |
|
| [34] |
Organization WH. Malaria by numbers: global and regional burden. Available at: https://www.who.int/campaigns/world-malaria-day/2023/background. (Accessed January 30, 2026) |
| [35] |
Cohen JI, Fauci AS, |
| [36] |
|
| [37] |
|
| [38] |
Gregoriadis G, Allison AC. Entrapment of proteins in liposomes prevents allergic reactions in pre-immunised mice. FEBS Lett 1974; 45(1): 71-4. |
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
Agency EM. Assessment report Comirnaty common name: COVID-19 mRNA vaccine (nucleoside-modified); EMEA/H/C/005735/0000; 2020. Available at: https://www.huber.embl.de/msmb/extras/comirnaty-epar-public-assessment-report_en.pdf. (Accessed January 30, 2026) |
| [43] |
|
| [44] |
|
| [45] |
Pfizer. Pfizer and BioNTech to Co-develop potential COVID-19 vaccine. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-co-develop-potential-covid-19-vaccine. (Accessed January 30, 2026) |
| [46] |
Fathizadeh H, Afshar S, Masoudi MR, Gholizadeh P, Asgharzadeh M, Ganbarov K, |
| [47] |
|
| [48] |
Let’s talk about lipid nanoparticles. Nat Rev Mater 2021; 6: 99. doi: 10.1038/s41578-021-00281-4. |
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
Bigini P, Gobbi M, Bonati M, Clavenna A, Zucchetti M, Garattini S, |
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, |
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
Pascolo S. Synthetic messenger RNA-based vaccines: from scorn to hype. Viruses 2021; 13(2): 270. |
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
Gennova. GEMCOVAC® mRNA vaccines for COVID-19. Available at: https://gennova.bio/gemcovac-19-2/. (Accessed January 30, 2026) |
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, |
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
Proffitt A. First HEV vaccine approved. Nat Biotechnol 2012; 30(4): 300-1. |
| [112] |
|
| [113] |
Yoshikawa H, Ebihara K, Tanaka Y, |
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
|
| [120] |
Medicago. Plant-derived vaccines. Available at: https://www.nature.com/articles/d43747-020-00537-y. (Accessed January 30, 2026) |
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
Karron RA, Luongo C, Woods S, Oliva J, Collins PL, Buchholz UJ, |
| [135] |
|
| [136] |
|
| [137] |
Tariq H, Batool S, Asif S, Ali M, Abbasi BH. Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases. Front Microbiol 2022; 12: 790121. |
| [138] |
|
| [139] |
Collins SM, Nice JB, Chang EH, Brown AC. Size exclusion chromatography to analyze bacterial outer membrane vesicle heterogeneity. J Vis Exp 2021(171): e62429. |
| [140] |
|
| [141] |
|
| [142] |
|
| [143] |
|
| [144] |
|
| [145] |
|
| [146] |
|
| [147] |
|
| [148] |
|
| [149] |
|
| [150] |
|
| [151] |
Yue H, Jiang J, Taylor AJ, Leite ADL, Dodds ED, |
| [152] |
Intravacc. OMV-Vacc technology. Available at: https://www.intravacc.nl/platforms/omv-vacc-technology. (Accessed January 30, 2026) |
| [153] |
|
| [154] |
|
| [155] |
|
| [156] |
|
| [157] |
|
| [158] |
Dykman LA. Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases. Expert Rev Vaccines 2020; 19(5): 465-77. |
| [159] |
Emergex. Emergex announces positive phase I trial data for DengueTcPTM, its novel T cell-priming immune set-point candidate. Available at: https://www.gyldenpharma.com/emergex-announces-positive-phase-i-trial-data-for-denguetcp-its-novel-t-cell-priming-immune-set-point-candidate/. (Accessed January 30, 2026) |
| [160] |
|
| [161] |
|
| [162] |
|
| [163] |
|
| [164] |
|
| [165] |
|
| [166] |
|
| [167] |
|
| [168] |
|
| [169] |
|
| [170] |
|
| [171] |
|
| [172] |
|
| [173] |
|
| [174] |
|
| [175] |
|
| [176] |
|
| [177] |
|
| [178] |
|
| [179] |
|
| [180] |
|
| [181] |
|
| [182] |
|
| [183] |
Escudier B, Dorval T, Chaput N, André F, |
| [184] |
|
| [185] |
|
| [186] |
|
| [187] |
|
| [188] |
|
| [189] |
Idumah CI. Emerging trends in poly (lactic-co-glycolic) acid bionanoarchitectures and applications. Cleaner Mater 2022; 5: 100102. |
| [190] |
|
| [191] |
|
| [192] |
|
| [193] |
Raj R, |
| [194] |
|
| [195] |
|
| [196] |
|
| [197] |
|
| [198] |
|
| [199] |
|
| [200] |
|
| [201] |
|
| [202] |
|
| [203] |
|
| [204] |
|
| [205] |
|
| [206] |
|
| [207] |
Shi S, Zhu H, Xia X, Liang Z, Ma X, |
| [208] |
|
| [209] |
|
| [210] |
|
| [211] |
|
| [212] |
|
| [213] |
|
| [214] |
|
| [215] |
|
| [216] |
|
| [217] |
Fehér K. Single stranded DNA immune modulators with unmethylated CpG motifs: structure and molecular recognition by toll-like receptor 9. Curr Protein Pept Sci 2019; 20(10): 1060-8. |
| [218] |
|
| [219] |
|
| [220] |
|
| [221] |
|
| [222] |
|
| [223] |
|
| [224] |
|
| [225] |
|
| [226] |
Novavax. Matrix-M® Adjuvant. Available at: https://www.novavax.com/science-technology/matrix-m-adjuvant. (Accessed January 30, 2026). |
| [227] |
|
| [228] |
|
| [229] |
|
| [230] |
|
| [231] |
|
| [232] |
Parums DV. First approval of the protein-based adjuvanted nuvaxovid (NVX-CoV2373) novavax vaccine for SARS-CoV-2 could increase vaccine uptake and provide immune protection from viral variants. Med Sci Monit 2022; 28: e936523. |
| [233] |
|
| [234] |
Smith G, Liu Y, Flyer D, Massare MJ, Zhou B, Patel N, |
| [235] |
|
| [236] |
|
| [237] |
|
| [238] |
|
| [239] |
|
| [240] |
|
| [241] |
|
| [242] |
|
| [243] |
|
| [244] |
|
| [245] |
Xu X, Zhang M, Liu X, Chai M, Diao L, Ma L, |
| [246] |
|
| [247] |
|
| [248] |
|
/
| 〈 |
|
〉 |